Trevi Therapeutics (TRVI) Accumulated Depreciation (2018 - 2025)

Trevi Therapeutics' Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $359000.0 for Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 57.46% year-over-year to $359000.0 in Q4 2025; TTM through Dec 2025 was $359000.0, a 57.46% increase from a year earlier, with the FY2025 full-year figure at $359000.0, up 57.46% from the prior year.
• Accumulated Depreciation advanced to $359000.0 in Q4 2025 per TRVI's latest filing, from $228000.0 in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $359000.0 in Q4 2025 and bottomed at $134000.0 in Q4 2023.
• The 5-year median for Accumulated Depreciation is $225000.0 (2022), against an average of $225600.0.
• Across the five-year window, Accumulated Depreciation slumped 40.44% in 2023 and jumped 70.15% in 2024, its largest moves.
• Year by year, Accumulated Depreciation stood at $182000.0 in 2021, then increased by 23.63% to $225000.0 in 2022, then slumped by 40.44% to $134000.0 in 2023, then soared by 70.15% to $228000.0 in 2024, then jumped by 57.46% to $359000.0 in 2025.
• Per Business Quant, the three latest TRVI Accumulated Depreciation figures stand at $359000.0 (Q4 2025), $228000.0 (Q4 2024), and $134000.0 (Q4 2023).